Trial · NCT06588738
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
NCT06588738, Phase 3, Completed, Alumis Inc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001. Trials, record NCT06588738. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06588738
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
- NCT number
- NCT06588738
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 862 participants, actual
- Lead sponsor
- Alumis Inc
- Conditions
- Plaque Psoriasis
- Interventions
- Envudeucitinib, Placebo, Apremilast
- First posted
- 2024-09-19
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo | 16 weeks | Proportion of patients achieving ≥75% reduction in PASI score. Proportion of patients achieving a score of 0 or 1 on sPGA. |
| Secondary | To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast | 24 weeks | Proportion of patients achieving of ≥90% or 100% reduction in PASI |
| Secondary | To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast | 24 weeks | Proportion of patients achieving of ≥75% reduction in PASI |
| Secondary | To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast | 24 weeks | Proportion of patients achieving a score of 0 or 1 on sPGA |
| Secondary | To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast | 24 weeks | Change from baseline in %BSA |
| Secondary | To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast | 24 weeks | Proportion of patients achieving a score of 0 or 1 on ssPGA |
| Secondary | To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast | 24 weeks | Proportion of patients achieving a score of 0 |
| Secondary | To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast | 24 weeks | Proportion of patients achieving a score of 0 or 1 |
| Secondary | To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo | 24 weeks | Change from baseline in Pruritus NRS (scale is from 0 (no pain) to 10 (severe pain)). |
| Secondary | Proportion of patients with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) | 24 weeks | Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06588738
GET https://conductscience.org/api/trials/v1/NCT06588738/registered